S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
NASDAQ:CRMD

CorMedix (CRMD) Stock Price, News & Analysis

$3.54
+0.01 (+0.28%)
(As of 02/28/2024 ET)
Today's Range
$3.51
$3.65
50-Day Range
$2.94
$3.92
52-Week Range
$2.57
$6.09
Volume
267,475 shs
Average Volume
387,864 shs
Market Capitalization
$194.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.25

CorMedix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
274.3% Upside
$13.25 Price Target
Short Interest
Bearish
14.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of CorMedix in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.86) to ($0.96) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.85 out of 5 stars

Medical Sector

780th out of 945 stocks

Pharmaceutical Preparations Industry

356th out of 431 stocks


CRMD stock logo

About CorMedix Stock (NASDAQ:CRMD)

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CRMD Stock Price History

CRMD Stock News Headlines

Cormedix Stock (NASDAQ:CRMD), Short Interest Report
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Cormedix Stock (NASDAQ:CRMD) Insider Trades
CorMedix Inc. Announces Appointment of Chief Legal Officer
Why CorMedix Stock Popped Wednesday
U.S. FDA approves CorMedix's antimicrobial drug
ARCT, MNTS and SNBR are among after hour movers
See More Headlines
Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRMD
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.25
High Stock Price Target
$19.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+269.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-29,700,000.00
Pretax Margin
-132,646.69%

Debt

Sales & Book Value

Annual Sales
$60,000.00
Book Value
$1.33 per share

Miscellaneous

Free Float
52,291,000
Market Cap
$196.77 million
Optionable
Optionable
Beta
1.79
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Joseph Todisco MBA (Age 48)
    CEO & Director
    Comp: $927.62k
  • Dr. Matthew T. David M.D. (Age 46)
    Executive VP & CFO
    Comp: $830.64k
  • Ms. Elizabeth Masson-Hurlburt B.A. (Age 45)
    Executive VP and Head of Clinical & Medical Affairs
    Comp: $538.91k
  • Ms. Kaufman Beth Zelnick Esq.
    Executive VP, Chief Legal Officer & Corporate Secretary
  • Donna Ucci
    Senior VP & Head of Global Quality
  • Dr. Tushar Mukherjee
    Senior VP & Head of Technical Operations
  • Ms. Erin Mistry (Age 42)
    Executive VP & Chief Commercial Officer














CRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell CorMedix stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRMD shares.
View CRMD analyst ratings
or view top-rated stocks.

What is CorMedix's stock price target for 2024?

4 equities research analysts have issued twelve-month target prices for CorMedix's shares. Their CRMD share price targets range from $10.00 to $19.00. On average, they expect the company's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 274.3% from the stock's current price.
View analysts price targets for CRMD
or view top-rated stocks among Wall Street analysts.

How have CRMD shares performed in 2024?

CorMedix's stock was trading at $3.76 on January 1st, 2024. Since then, CRMD shares have decreased by 5.9% and is now trading at $3.54.
View the best growth stocks for 2024 here
.

Are investors shorting CorMedix?

CorMedix saw a increase in short interest in February. As of February 15th, there was short interest totaling 7,730,000 shares, an increase of 7.5% from the January 31st total of 7,190,000 shares. Based on an average daily volume of 471,100 shares, the days-to-cover ratio is presently 16.4 days.
View CorMedix's Short Interest
.

When is CorMedix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our CRMD earnings forecast
.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NASDAQ:CRMD) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.01 million.

What ETF holds CorMedix's stock ?

Amplify Treatments, Testing and Advancements ETF holds 12,811 shares of CRMD stock, representing 0.39% of its portfolio.

When did CorMedix's stock split?

CorMedix shares reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL).

Who are CorMedix's major shareholders?

CorMedix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nomura Holdings Inc. (5.38%), Vanguard Group Inc. (5.15%), Nuveen Asset Management LLC (0.44%), Barclays PLC (0.40%), Charles Schwab Investment Management Inc. (0.28%) and Bridgeway Capital Management LLC (0.27%). Insiders that own company stock include Elizabeth Masson-Hurlburt, Joseph Todisco, Matthew T David and Myron Kaplan.
View institutional ownership trends
.

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRMD) was last updated on 2/28/2024 by MarketBeat.com Staff